Zobrazeno 1 - 10
of 325
pro vyhledávání: '"Cegolon L"'
Autor:
Rostami Z, Mastrangelo G, Einollahi B, Nemati E, Shafiee S, Ebrahimi M, Javanbakht M, Saadat SH, Amini M, Einollahi Z, Beyram B, Cegolon L.
Publikováno v:
Frontiers in Immunology. 13
BackgroundSeveral reports suggested that acute kidney injury (AKI) is a relatively common occurrence in hospitalized COVID-19 patients, but its prevalence is inconsistently reported across different populations. Moreover, it is unknown whether AKI re
Autor:
Caminati, M.1, Cegolon, L.2 l.cegolon@gmail.com, Bacchini, M.3, Segala, N.3, Dama, A.4, Bovo, C.5, Olivieri, B.6, Furci, F.7, Senna, G.1
Publikováno v:
BMC Public Health. 1/5/2021, Vol. 21 Issue 1, p1-8. 8p. 4 Charts, 1 Graph.
Autor:
Cegolon, L.1,2 l.cegolon@gmail.com, Maso, G.1, Heymann, W. C.3,4, Bortolotto, M.5, Cegolon, A.6, Mastrangelo, G.7
Publikováno v:
Scientific Reports. 4/6/2020, Vol. 10 Issue 1, p1-17. 17p.
Autor:
Cegolon, L.1,2 l.cegolon@gmail.com, Mastrangelo, G.3, Maso, G.1, Dal Pozzo, G.4, Ronfani, L.1, Cegolon, A.5, Heymann, W. C.6,7, Barbone, F.1
Publikováno v:
Scientific Reports. 1/15/2020, Vol. 10 Issue 1, p1-18. 18p.
Autor:
Cegolon, L.1,2 l.cegolon@gmail.com, Mastrangelo, G.3, Heymann, W. C.4,5, Dal Pozzo, G.6, Ronfani, L.2, Barbone, F.2
Publikováno v:
Scientific Reports. 12/19/2019, Vol. 9 Issue 1, p1-16. 16p.
Publikováno v:
Occupational and Environmental Medicine, 2012 Mar 01. 69(3), 227-228.
Externí odkaz:
https://www.jstor.org/stable/23218116
Autor:
Cegolon, L.1,2 (AUTHOR) l.cegolon@gmail.com, Mastrangelo, G.3 (AUTHOR), Maso, G.1 (AUTHOR), Dal Pozzo, G.4 (AUTHOR), Ronfani, L.1 (AUTHOR), Cegolon, A.5 (AUTHOR), Heymann, W. C.6,7 (AUTHOR), Barbone, F.1 (AUTHOR)
Publikováno v:
Scientific Reports. 3/17/2021, Vol. 11 Issue 1, p1-3. 3p.
Autor:
Cegolon, L.1,2 l.cegolon@gmail.com, Mastrangelo, G.3, Heymann, W. C.4,5, Dal Pozzo, G.6, Ronfani, L.2, Barbone, F.2
Publikováno v:
Scientific Reports. 4/10/2020, Vol. 10 Issue 1, p1-3. 3p.
Background: Omalizumab is a recombinant anti-immunoglobulin E (IgE) antibody used in the treatment of patients with chronic spontaneous urticaria (CSU). Objective: This multicentric study assessed the safety and efficacy of omalizumab in patients (n=
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::26b016db69b86ae64d4f09769eca731e
http://hdl.handle.net/11368/2999490
http://hdl.handle.net/11368/2999490
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.